Skip to main content

Table 2 Analytes that differ significantly between MPS IVA and unaffected control subjects

From: Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers

Analyte

p-value

Significantly higher in MPSIVA patients versus unaffected controls

 

MDC (macrophage-derived chemokine

0.047

MIP-1 alpha (macrophage inflammatory protein-1 alpha)*

0.014

MMP-2 (matrix metalloproteinase-2)*†

0.003

Significantly lower in MPSIVA patients versus unaffected controls

 

Alpha-1-antitrypsin

0.006

Alpha-fetoprotein

0.001

C-reactive protein

0.000

EN-RAGE (extracellular newly-identified receptor for advanced glycosylation end products)

0.000

Eotoxin

0.001

Erythropoietin

0.000

Factor VII

0.028

Ferritin

0.019

IFN-gamma (interferon-gamma)

0.001

IL-RA (interleukin-1 receptor antagonist)

0.000

Leptin*

0.000

Lipoprotein (a)*

0.000

MCP-1 (monocyte chemotactic protein 1)

0.009

Myeloperoxidase

0.036

Prostatic acid phosphatase

0.000

Serum amyloid P*

0.006

  1. * These analytes were also significantly different between the high and low uKS groups of MPS IVA patients (see table 5).
  2. † This analyte was also significantly different between the older and younger age groups of MPS IVA patients (see table 3).
  3. Note: The following analytes were also tested but not found to be statistically significantly different between MPS IVA and unaffected individuals: adiponectin, alpha-2-macroglobulin, apolipoprotein A-I, apolipoprotein C-III, apolipoprotein H, apolipoprotein (a), beta-2-microglobulin, brain-derived neurotrophic factor, calcitonin, cancer antigen 125, cancer antigen 19-9, carcinoembryonic antigen, CD40 antigen, CD40 ligand, complement C3, creatine kinase-MB, endothelin-1, epidermal growth factor, epithelial-derived neutrophil-activating protein 78, fatty acid-binding protein (heart), fibrinogen, fibroblast growth factor basic, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, growth hormone, haptoglobulin, immunoglobulin A, immunoglobulin E, immunoglobulin M, insulin, insulin-like growth factor I, intercellular adhesion molecule 1, interleukin-1 alpha, interleukin-1 beta, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-10, interleukin-12 subunit p40, interleukin-12 subunit p70, interleukin-13, interleukin-15, interleukin-16, lymphotactin, macrophage inflammatory protein 1-beta, matrix metalloproteinase-3, matrix metalloproteinase-9, myoglobulin, plasminogen activator inhibitor 1, pregnancy-associated plasma protein A, prostate-specific antigen (free), RANTES/CCL5 (regulated upon activation, normal T-cell expressed and secreted), serum glutamic oxaloacetic transaminase, sex hormone-binding globulin, stem cell factor, thrombopoietin, thyroid-stimulating hormone, thyroxine-binding globulin, tissue factor, tissue inhibitor of metalloproteinase 1, tumor necrosis factor alpha, tumor necrosis factor beta, tumor necrosis factor receptor-like 2, vascular cell adhesion molecule-1, vascular endothelial growth factor, and von Willebrand factor.
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172